Vigil Neuroscience, Inc. (VIGL) Financial Analysis & Valuation | Quarter Chart
Vigil Neuroscience, Inc. (VIGL)
VIGLPrice: $8.05
Fair Value: 🔒
🔒score
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is des... more
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifyi... more
Description
Shares
| Market Cap | $375.71M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Ivana Magovcevic-Liebisch |
| IPO Date | 2022-01-07 | CAGR | — |
| Employees | 69 | Website | www.vigilneuro.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
VIGL chart loading...
Fundamentals
Technicals
| Enterprise Value | $349.80M | P/E Ratio | -3.83 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 831.21 | P/B Ratio | 9.29 |
| P/CF Ratio | -6.59 | P/FCF Ratio | -6.42 |
| EPS | $-2.1 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -76.63% | Gross Margin | -0.03% |
| Operating Margin | -214.05% | Profit Margin | -203.9% |
| ROE | -1.38% | ROA | -1.06% |
| ROCE | -1.84% | Current Ratio | 2.06 |
| Quick Ratio | 2.06 | Cash Ratio | 1.21 |
| Debt/Equity | 0.3 | Interest Coverage | — |
| Altman Z Score | -3.93 | Piotroski Score | 1 |